Core Viewpoint - A class action lawsuit has been filed against Bath & Body Works, Inc. and certain senior executives for securities fraud following significant stock drops attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Ohio, captioned Lingam v. Bath & Body Works, Inc., et al., No. 2:26-cv-00039 [3]. - Investors have until March 16, 2026, to request to be appointed to lead the case [3]. Group 2: Company Performance and Strategy - Bath & Body Works is a specialty retailer focusing on home fragrance and body care products, exploring product categories beyond its core business, including men's products, lip care, hair care, and laundry [4]. - The company claimed that customers were responding favorably to its innovations and that its strategy was effective in driving topline growth through category adjacencies [5]. Group 3: Stock Performance - On August 28, 2025, Bath & Body Works reported disappointing Q2 2025 financial results, cutting its full-year earnings guidance by $0.03 to a range of $3.28 to $3.53, leading to a stock price drop of $2.18 per share, or 6.9% [6]. - Following the Q3 2025 financial results on November 20, 2025, which revealed that the strategy of pursuing adjacencies had not grown the customer base, the stock price fell by $5.22 per share, or 24.8% [7].

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and its senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Middle District of Tennessee, captioned Postiwala v. Ardent Health, Inc., et al., No. 3:26-cv-00022 [3]. - Investors have until March 9, 2026, to request to be appointed to lead the case [3]. - The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Ardent Health securities [3]. Group 2: Allegations Against Ardent Health - Ardent Health is accused of misrepresenting its process for determining the collectability of accounts receivable, claiming to rely on "detailed reviews of historical collections" while actually using a "180-day cliff" method [4]. - This misrepresentation allegedly allowed Ardent Health to report inflated accounts receivable and delay recognizing losses on uncollectable accounts, constituting a violation of federal securities laws [4]. Group 3: Stock Price Impact - On November 12, 2025, Ardent Health announced a $43 million decrease in revenue for the quarter and a $54 million increase in professional liability reserves, leading to a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 [5].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to be appointed to lead the case [3]. Group 2: Company Performance and Allegations - Integer designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices [4]. - The company allegedly overstated demand for its electrophysiology devices while public assurances contradicted the actual decline in demand and revenue [5]. - On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations [6]. Group 3: Stock Price Impact - Following the announcement of lowered sales guidance, Integer's stock price dropped by $35.22 per share, or over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].

Core Viewpoint - Carvana Co. is under investigation for potential violations of federal securities laws due to significant stock price drops linked to claims of accounting improprieties [2][3]. Company Overview - Carvana is an online e-commerce platform and used-car retailer that enables customers to buy, sell, or finance vehicles entirely online. A substantial portion of its revenue is derived from online vehicle sales and auto loans, which are often securitized or sold to external parties [3]. Investigation Details - The investigation by Bleichmar Fonti & Auld LLP focuses on whether Carvana overstated its earnings and improperly accounted for related party transactions [3]. - Gotham City Research LLC issued a report alleging that Carvana's financial results are closely tied to a network of related party entities controlled by Ernest Garcia II, which includes DriveTime, Bridgecrest, and GoFi. The report claims that these relationships led to an overstatement of Carvana's earnings by over $1 billion [4]. Stock Performance - Following the release of the Gotham City report on January 28, 2026, Carvana's stock price fell over 20%, dropping from $474.06 per share at market open to a low of $374.55 per share [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Smart Digital Group Limited due to allegations of securities law violations, urging affected investors to contact them for legal options [2][5]. Group 1: Allegations Against Smart Digital - The complaint alleges that Smart Digital and its executives made false or misleading statements and failed to disclose significant risks related to market manipulation and fraudulent promotion schemes [5]. - Specific allegations include the use of social media misinformation and impersonation by individuals posing as financial professionals to manipulate the stock price [5]. - It is claimed that insiders used offshore accounts to facilitate the dumping of shares during a price inflation campaign, which was not disclosed in the company's public statements [5]. Group 2: Stock Price Collapse and SEC Actions - On September 26, 2025, Smart Digital's stock price fell by 86.4%, closing at $1.85 per share, following a trading halt by NASDAQ due to volatility [6]. - The SEC suspended trading of Smart Digital securities from September 29, 2025, to October 10, 2025, citing potential manipulation through social media recommendations designed to inflate stock prices [6]. - Following the SEC's suspension, NASDAQ also suspended trading in Smart Digital securities pending further information, with no clear timeline for resumption [6]. Group 3: Legal Proceedings and Class Action - Investors who suffered losses are encouraged to seek the role of lead plaintiff in a federal securities class action against Smart Digital, with a deadline set for March 16, 2026 [2][7]. - The lead plaintiff is defined as the investor with the largest financial interest in the case, who will oversee the litigation on behalf of the class [7]. - Faruqi & Faruqi, LLP is also seeking information from whistleblowers, former employees, and shareholders regarding Smart Digital's conduct [8].

Core Viewpoint - Kahn Swick & Foti, LLC has initiated class action securities lawsuits against Coupang, Inc. for alleged securities fraud affecting investors during the specified period [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors adversely affected by alleged securities fraud between May 7, 2025, and December 16, 2025 [2]. - Coupang and certain executives are accused of failing to disclose material information, violating federal securities laws [3]. - Allegations include inadequate cybersecurity protocols that allowed unauthorized access to sensitive customer information for nearly six months, leading to heightened regulatory and legal scrutiny [3]. - The defendants allegedly failed to report the data breach in compliance with Securities and Exchange Commission reporting rules, rendering their public statements materially false and misleading [3]. Group 2: Legal Proceedings - The first-filed case is Barry v. Coupang, Inc., et al., No. 25-cv-10795, with a subsequent case, Lee v. Coupang, Inc., et al., No. 26-cv-00047, expanding the class period [4]. - Investors have until February 17, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require this role [4]. Group 3: About Kahn Swick & Foti, LLC - Kahn Swick & Foti, LLC is recognized as one of the premier boutique securities litigation law firms in the U.S., with a ranking among the top 10 firms nationally based on total settlement value [4]. - The firm serves a diverse clientele, including public and private institutional investors, as well as retail investors, seeking recoveries for investment losses due to corporate fraud or malfeasance [4].

Company Overview - Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for individuals with rare kidney and metabolic diseases in the United States [2]. Investigation Details - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere, specifically whether the company and certain executives made materially false and/or misleading statements or omitted material information regarding Travere's business and operations [1][2]. Law Firm Background - Robbins Geller is recognized as one of the leading law firms in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in securities-related class action cases in 2024, which is more than the next five law firms combined [3].

Company Overview - NuScale Power Corporation is a provider of small modular reactor nuclear technology [2] Investigation Details - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving NuScale Power Corporation [1] - The investigation focuses on whether NuScale and certain top executives made materially false and/or misleading statements or omitted material information regarding the company's business and operations [2]

Core Viewpoint - A class action lawsuit has been filed against Ramaco Resources, Inc. due to allegations of misleading statements regarding the company's Brook Mine operations, which reportedly did not commence significant mining activity as claimed [1][4]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the Southern District of New York, under the case caption Henning v. Ramaco Resources, Inc., and covers the period from July 31, 2025, to October 23, 2025 [1]. - The lawsuit claims violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, asserting that the defendants made materially false and misleading statements about the company's business and operations [1][4]. Group 2: Allegations Against Ramaco - Wolfpack Research published a report on October 23, 2025, alleging that Ramaco's Brook Mine was a "hoax" and that no active mining work had occurred since its groundbreaking in July [3]. - The report indicated that drone footage taken three months after the mine's opening showed no active work, contradicting the company's claims of progress [3]. - Following the report, Ramaco's stock price dropped by $3.81, or 9.6%, closing at $36.01 per share on October 23, 2025, with unusually high trading volume [3]. Group 3: Misleading Statements - The complaint alleges that the defendants failed to disclose critical information, including the lack of significant mining activity at the Brook Mine and the overstated development progress [4]. - It is claimed that the positive statements made by the defendants regarding the company's operations were materially misleading and lacked a reasonable basis [4].

Core Viewpoint - A class action lawsuit has been filed against Fermi Inc. for allegedly misleading investors regarding tenant demand and funding commitments for its Project Matador campus, leading to significant financial losses for shareholders [4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased securities from September 28, 2025, to December 11, 2025, alleging that Fermi overstated tenant demand and the reliance on a single tenant's funding for Project Matador [4]. - The lawsuit claims there was a significant risk that the primary tenant would terminate its funding commitment, which ultimately occurred [4]. Group 2: Financial Impact - Fermi began trading on NASDAQ at $21.00 per share on October 1, 2025, but after the announcement of the termination of a $150 million funding agreement on December 12, 2025, the share price dropped by $5.16, or approximately 33.8%, closing at $10.09 [5].